NewAmsterdam Pharma Company N.V.
Income Statement
| Line Item | Aug 2026 | Jun 2026 | Apr 2026 | Mar 2026 | Feb 2026 | Dec 2025 | Oct 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $3.7M | — | $3.0M | — | — | — | $348.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | $41.7M | — | $38.0M | — | — | — | $31.0M |
| SG&A Expense | — | $26.9M | — | $23.5M | — | — | — | $24.5M |
| Operating Income | — | $-64.9M | — | $-58.4M | — | — | — | $-55.1M |
| Operating Margin | — | -1,752.6% | — | -1,921.7% | — | — | — | -15,845.7% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | $-64.1M | — | $-48.4M | — | — | — | $-72.0M |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | — | $-64.1M | — | $-48.4M | — | — | — | $-72.0M |
| Net Margin | — | -1,732.9% | — | -1,593.5% | — | — | — | -20,691.1% |
| EPS (Basic) | — | $-0.52 | — | $-0.40 | — | — | — | $-0.61 |
| EPS (Diluted) | — | $-0.52 | — | $-0.40 | — | — | — | $-0.61 |
| Shares Outstanding (Basic) | 119.5M | 123.4M | 116.9M | 121.7M | 115.0M | 114.4M | 113.4M | 119.0M |
| Shares Outstanding (Diluted) | 119.5M | 123.4M | 116.9M | 121.7M | 115.0M | 114.4M | 113.4M | 119.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |